Understanding the spectrum of rhino-orbito-cerebral mucormycosis: clinical presentation, management strategies, and prognostic markers in an Indian tertiary care setting

Sanjay Kishve; Prajakta Kishve; G. Pavan Kalyan Reddy

doi:10.18203/2320-6012.ijrms20243365

Authors

Sanjay Kishve Department of Otorhinolaryngology, Employees’ State Insurance Corporation Medical College, Hyderabad, Telangana, India
Prajakta Kishve Department of Otorhinolaryngology, Employees’ State Insurance Corporation Medical College, Hyderabad, Telangana, India
G. Pavan Kalyan Reddy Department of Otorhinolaryngology, Employees’ State Insurance Corporation Medical College, Hyderabad, Telangana, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20243365

Keywords:

Rhino-orbito-cerebral mucormycosis, COVID-19, Diabetes mellitus

Abstract

Background: Rhino-orbito-cerebral mucormycosis (ROCM) is an angio-invasive fungal infection characterized by tissue infarction and necrosis. Its incidence has surged, particularly in the backdrop of the ongoing COVID-19 pandemic, necessitating a comprehensive understanding of its clinical presentation, management outcomes, and prognostic factors.

Methods: This retrospective cohort study analyzed data from 100 ROCM patients admitted to a tertiary care hospital in India between February 2021 and September 2021. Clinical presentations, laboratory investigations, treatment outcomes, and adverse reactions were assessed. Associations between comorbidities (diabetes mellitus, COVID-19) and mortality were analyzed using odds ratios, and relative risks.

Results: The study cohort comprised 55 male and 45 female patients, with a mean age of 52 years. Diabetes mellitus was prevalent in 83% of patients, with 80% testing positive for COVID-19. Common presenting symptoms included ophthalmoplegia (71%) and diminution of vision (58%). Initial investigations revealed a high incidence of paranasal sinusitis and maxillary osteomyelitis. Treatment involved intravenous liposomal Amphotericin-B and aggressive surgical debridement. The mortality rate was 17%, with diabetes mellitus and COVID-19 significantly associated with mortality.

Conclusions: ROCM presents substantial morbidity and mortality, particularly among patients with comorbidities such as diabetes mellitus and COVID-19. Early diagnosis, prompt initiation of antifungal therapy, and aggressive surgical intervention are essential for improving patient outcomes. Multidisciplinary collaboration and proactive management strategies are imperative in addressing the challenges posed by this invasive fungal infection.

Metrics

Metrics Loading ...

References

Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-53.

Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(1):S23-34.

Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel). 2019;5(1):26.

Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and Diagnosis of Mucormycosis: An Update. J Fungi (Basel). 2020;6(4):265.

Prakash H, Chakrabarti A. Epidemiology of Mucormycosis in India. Microorganisms. 2021;9(3):523.

John TM, Jacob CN, Kontoyiannis DP. When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. J Fungi (Basel). 2021;7(4):298.

Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54(1):S16-22.

Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146.

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al; Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-21.

Chander J. Textbook of medical mycology. 4th edition. New Delhi: Mehta Publishers. 2020.

Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26(7):944.

Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol. 2012;50(6):611-8.

Mignogna MD, Fortuna G, Leuci S, Adamo D, Ruoppo E, Siano M, et al. Mucormycosis in immunocompetent patients: a case-series of patients with maxillary sinus involvement and a critical review of the literature. Int J Infect Dis. 2011;15(8):e533-40.